Legend Biotech (NASDAQ:LEGN) Given Buy Rating at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Legend Biotech (NASDAQ:LEGN – Free Report) in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a $73.00 price objective on the stock. HC Wainwright also issued estimates for Legend Biotech’s Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($1.22) […]
More Stories
Crescent Sterling Ltd. Sells 162 Shares of Phillips 66 (NYSE:PSX)
Crescent Sterling Ltd. lessened its holdings in Phillips 66 (NYSE:PSX – Free Report) by 1.1% during the fourth quarter, according...
Schwab Short-Term U.S. Treasury ETF (NYSEARCA:SCHO) Shares Acquired by EWG Elevate Inc.
EWG Elevate Inc. lifted its position in shares of Schwab Short-Term U.S. Treasury ETF (NYSEARCA:SCHO – Free Report) by 127.9%...
Crescent Sterling Ltd. Sells 500 Shares of Vanguard Large-Cap ETF (NYSEARCA:VV)
Crescent Sterling Ltd. lessened its position in shares of Vanguard Large-Cap ETF (NYSEARCA:VV – Free Report) by 14.3% in the...
SOLVE (SOLVE) Price Tops $0.0052 on Exchanges
SOLVE (SOLVE) traded 8.1% lower against the dollar during the 1-day period ending at 9:00 AM ET on January 13th....
Moon Tropica (CAH) Trading 21.6% Lower This Week
Moon Tropica (CAH) traded 2.4% lower against the dollar during the 24-hour period ending at 9:00 AM E.T. on January...
Vow Self Reported Market Capitalization Tops $21.98 Million (VOW)
Vow (VOW) traded 16.7% lower against the US dollar during the 1 day period ending at 9:00 AM Eastern on...